LNSR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• was $39.9 million for the six months ended June 30, 2026 compared to a net loss of $29.1 million for the six months ended June 30, 2025. Our installed base of Systems is approximately 445 as of June 30, 2026.

• standard limited warranty. In some situations, we lease our Systems to surgeons, primarily through non-cancellable leases with a fixed lease payment. The following table provides information about revenue and revenue attributable to recurring sources, which we consider to be all components of our re…

• Changes in our tax rates or exposure to additional tax liabilities could adversely affect our earnings and financial condition. On July 4, 2025, new U.S. tax legislation was signed into law (known as the “One Big Beautiful Bill Act” or “OBBBA”) which made permanent many of the tax provisions enacted…

• the OBBBA made changes to certain U.S. corporate tax provisions, many of which became effective in 2026. Based on the Company’s analysis of the provisions, the Company determined that the tax law changes do not have a material impact on the Company’s financial statements. However, the Company will c…

• Three Months Ended June 30, 2026 compared with the Three Months Ended June 30, 2025

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• On March 23, 2025, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Alcon Research, LLC, or Alcon, and VMI Option Merger Sub, Inc., or Merger Sub, which provided that, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub would merge with and…

• On May 21, 2025, we and Alcon each received a request for additional information and documentary material from the Federal Trade Commission, or the FTC, in connection with the FTC’s review of the Merger. Following its investigation, the FTC indicated its intention to seek to enjoin the Merger. On Ma…

• During the three months ended March 31, 2026, acquisition-related costs were reduced by $4.4 million associated with previously recognized acquisition-related costs eliminated in conjunction with the terminated Merger Agreement as compared to $4.2 million of acquisition-related costs incurred during…

• all of the features from our LLS with a dual-modality laser, integrated in a small, compact cataract treatment system that is designed to allow surgeons to perform a sterile laser-assisted cataract surgery in a single operating room or in-office surgical suite.

• Changes in our tax rates or exposure to additional tax liabilities could adversely affect our earnings and financial condition. On July 4, 2025, new U.S. tax legislation was signed into law (known as the “One Big Beautiful Bill Act” or “OBBBA”) which made permanent many of the tax provisions enacted…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• In addition, we are exposed to changes in interest rates under the Revolving Credit Facility. Borrowings under the Revolving Credit Facility bear interest at the 1-month term SOFR plus 3%, which reduces to 1-month term SOFR plus 2.5% if no event of default occurs in the first year. As of August 13, …

• Financial instruments that potentially subject us to concentrations of credit risk principally consist of accounts receivable and notes receivable. We limit our credit risk with respect to accounts receivable and notes receivable by performing credit evaluations when deemed necessary, but we do not …

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Financial instruments that potentially subject us to concentrations of credit risk principally consist of accounts receivable and notes receivable. We limit our credit risk with respect to accounts receivable and notes receivable by performing credit evaluations when deemed necessary, but we do not …

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Our debt arrangements contain certain covenants and restrictions that may limit our flexibility in operating our business, and any failure to satisfy those covenants and restrictions could adversely affect our business and financial condition.

• The agreement governing our Revolving Credit Facility (the “Credit Agreement”) contains various affirmative and negative covenants and restrictions that limit our ability to engage in specific types of transactions, including limitations on our ability to:

• incur or guarantee additional indebtedness or make payment on certain debt;

• pay dividends and make other distributions on, or redeem or repurchase, capital stock;

• make certain investments, including loans to other parties and forming new subsidiaries;

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. In addition, if we raise additional capital through collab…

• tariffs or other trade barriers, we would have to seek alternative sources of supply. Because of factors such as the proprietary nature of our products, our quality control standards and regulatory requirements, we may experience delays in engaging additional or replacement suppliers for certain com…

• Adequate coverage and reimbursement from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs, for certain procedures using our ALLY System or other products we may develop in the future, if approved, is central to the acc…

• Physicians are reimbursed separately for their professional time and effort to perform a cataract procedure that is covered by third-party payors. Such party payors regularly update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. Thi…

• and reimbursement among payors in the United States. Therefore, coverage and reimbursement for procedures can differ significantly from payor to payor. Many private payors require extensive documentation of a multi-step diagnosis before authorizing procedures using our products. Some private payors …

Text added vs the prior filing · source: 10-Q · 2026-08-13

• (a) The information set forth below is included for the purpose of providing disclosure under Item 1.01 – “Entry into a Material Definitive Agreement” of Form 8-K.

• On August 10, 2026, the Company entered into a Loan and Security Agreement (the “Credit Agreement”) with Salem Five Cents Savings Bank (the “Lender”), providing for a $10.0 million asset-based revolving credit facility (the “Revolving Credit Facility”) secured by a first priority perfected security …

• The amount available to borrow under the Revolving Credit Facility is based on certain accounts receivable and future lease receivables. Borrowings under the Revolving Credit Facility bear interest at the 1-month term SOFR plus 3%, which reduces to 1-month term SOFR plus 2.5% if no event of default …

• The Credit Agreement contains customary conditions precedent, representations and warranties, affirmative and negative covenants, events of default and indemnities. Certain changes of control with respect to the Company would constitute an event of default under the Credit Agreement. Upon the occurr…

• In addition, the Credit Agreement requires the Company to maintain a minimum of $3.0 million in cash on deposit with the Lender until the Company demonstrates compliance with a minimum EBITDA covenant for the fiscal year ending December 31, 2026 and to be in compliance with a 1.25 to 1.00 debt servi…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• (c) During the three months ended March 31, 2026, no directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” and/or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Re…